Jinsol Kim
Associate Principal
专长:
Consulting (Strategy Management & Regulatory), Consulting (Strategy Management and HTA requirements)
Jinsol Kim is an Associate Principal at EVERSANA. With a background in economics and years of consulting experience in healthcare and pharmaceuticals, he assists pharma companies in making strategic decisions in complex environments for market entry, portfolio optimization, asset valuation, and market assessment.
He has experience in working across numerous therapy areas including oncology, immunology, hematology, nephrology, infectious diseases, and rare diseases within the US, EU5, and APAC.
Representative engagements include:
- Developing launch options for the therapy area portfolio with both small molecules and biologics evaluating the options by building a probabilistic model from patient numbers and testing assumptions on epidemiology, biologics penetration, market shares, and compliance in different reimbursement schemes and price levels as part of a regional strategy effort
- Establishing the product positioning for an oncology pipeline asset in key reimbursed markets in APAC
- Building a valuation model for an early-stage asset and conducting sensitivity analysis to identify critical risks and scenario analysis to assess the full range of NPV at each trial phase
- Assessing market dynamics and potential market opportunity for a small molecule in G7 markets
- 在一些欧洲国家/地区中,针对罕见疾病适应症,为引进授权的候选药物制定定价和市场准入战略。
- Devising a regional and country-level launch strategy in major reimbursed APAC markets for a major big pharma with multiple drugs approved for the disease spectrum in multiple therapy areas including oncology
他擅长在资产和投资组合层面开发概率模型,进行评估和模拟。
He holds a BA in Economics from the University of California at Berkeley.